Catalog No.: PC-35358Not For Human Use, Lab Use Only.
BL5923 (BL-5923) is a potent, highly specific, orally available inhibitor of CCR1 with IC50 of 20.4 and 22.8 nM for human and mouse CCR1, resepctively.
BL5923 (BL-5923) is a potent, highly specific, orally available inhibitor of CCR1 with IC50 of 20.4 and 22.8 nM for human and mouse CCR1, resepctively.
BL5923 displays excellent selectivity against a panel of additional chemokine receptors including human CCR2, CCR4, CCR5, CCR6, CCR7, CXCR1, CXCR2, and CXCR3.
BL5923 suppresses colon cancer liver metastasis by blocking accumulation of immature myeloid cells in a mouse mode.
BL5923 ameliorates the progression of lupus nephritis in NZB/W mice; also improves survival, decreases the kidney fungal burden and protects from renal tissue injury in Candida-infected mice.
1. Kitamura T, et al. Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13063-8.
2. Revesz L, et al. Bridged piperazines and piperidines as CCR1 antagonists with oral activity in models of arthritis and multiple sclerosis. Lett Drug Des Discov. 2006;3:689–694.
3. Bignon A, et al. J Immunol. 2014 Feb 1;192(3):886-96.
4. Lionakis MS, et al. Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e02365-16.
